AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: AstraZeneca is conducting a Phase III clinical trial titled ‘SERENA-6’ to evaluate the efficacy of AZD9833, a next-generation oral SERD, in combination with a CDK4/6 inhibitor, compared to continuing aromatase inhibitors with a CDK4/6 inhibitor in patients with HR-positive, HER2-negative metastatic breast cancer with detectable ESR1 mutation. The study aims to determine if AZD9833 can improve outcomes in patients who have not progressed during first-line treatment.
Intervention/Treatment: The trial tests AZD9833, an experimental drug, combined with CDK4/6 inhibitors like palbociclib, abemaciclib, or ribociclib. It is compared against standard aromatase inhibitors (letrozole or anastrozole) with the same CDK4/6 inhibitors, targeting improved treatment efficacy in patients with ESR1 mutations.
Study Design: This interventional study uses a randomized, parallel assignment model with triple masking (participant, care provider, investigator). The primary purpose is treatment, aiming to assess the superiority of AZD9833 in delaying disease progression compared to standard treatment.
Study Timeline: The study began on June 30, 2021, and is currently active but not recruiting. The latest update was submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could influence treatment protocols.
Market Implications: Positive outcomes from this study could significantly impact AstraZeneca’s stock performance by strengthening its oncology portfolio and offering a competitive edge in the breast cancer treatment market. Success could also shift investor sentiment positively, given the high prevalence of breast cancer and the demand for more effective treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.